Definitive Healthcare Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 3, 2022, by Definitive Healthcare Corp. (Nasdaq: DH), a Delaware corporation. The filing primarily addresses significant executive leadership changes and references the announcement of financial results for the first quarter ended March 31, 2022.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing financial results for the quarter ended March 31, 2022. However, this specific Form 8-K text does not provide numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the incorporated press release for specific financial data.
Material Changes and Executive Leadership
The most significant material change reported is the transition of the company's Chief Executive Officer (CEO) role:
- Appointment of New CEO: Robert Musslewhite, currently the Company's President, was appointed CEO effective August 1, 2022.
- Transition of Founder: Jason Krantz, the Company's founder and current CEO, will step down as CEO on August 1, 2022, to assume the role of Executive Chairman of the Board.
- Board Membership: Mr. Musslewhite will continue to serve as a member of the Board of Directors.
Compensation and Employment Agreements
New employment agreements were executed on May 4, 2022, detailing the following terms:
Robert Musslewhite (Incoming CEO)
- Base Salary: $429,000 annually.
- Equity Grants:
- 333,322 RSUs vesting 30% on the first anniversary of May 4, 2022, followed by quarterly vesting over 30 months.
- 83,333 RSUs vesting 25% on the first anniversary, followed by quarterly vesting over three years.
- 125,000 RSUs cliff-vesting after a three-year performance period based on Total Shareholder Return versus the Nasdaq Composite index of SaaS and Health Care IT companies.
- Severance: Includes 12 months of base salary and bonus acceleration for termination without cause or for good reason. In a Change of Control scenario, this increases to 18 months of salary and 1.5x the annual bonus.
Jason Krantz (Executive Chairman)
- Base Salary: Remains at $428,655 for 2022; reduced to 75% of that amount for 2023.
- Equity Grants: Eligible for RSUs equal to 75% of the annual grants made to the CEO in fiscal year 2023.
- Non-Compete: Subject to non-competition and non-solicitation provisions for two years post-employment.
Outlook and Risks
The filing does not contain specific forward-looking guidance, risk factors, or management commentary regarding future financial performance beyond the leadership transition. The primary risk highlighted is the operational impact of the CEO transition scheduled for August 1, 2022.
Key Facts for Investor Verification
- Verify the specific Q1 2022 financial results (revenue, net income, cash flow) in the press release attached as Exhibit 99.1, as these figures are not listed in the 8-K text.
- Confirm the effective date of the leadership transition is August 1, 2022.
- Review the full text of the Musslewhite Employment Agreement (Exhibit 10.1) and Krantz Executive Chairman Agreement (Exhibit 10.2) for complete terms regarding performance metrics and severance triggers.
- Note that Mr. Musslewhite brings prior experience as CEO of OptumInsight and The Advisory Board Company.